Current Treatment
HMG-CoA reductase inhibitors, also known as statins, lower LDL-C and have demonstrated significant reduction in reducing cardiovascular events. 1 Guidelines from the American College of Cardiology and the American Heart Association on treating hyperlipidemia to reduce cardiovascular risk recommend initiating a statin depending on a patient's risk factors and the 10-year risk for atherosclerotic cardiovascular disease events. 2 This initial strategy was reiterated in a recent commentary discussing new research and therapies. Despite statins' efficacy, residual risk remains. As statins' effect on non-LDL-C levels is limited, drugs targeting non-LDL-C levels may complement statins' benefit and further reduce cardiovascular risk. 1
New Treatment Options
Cholesterol ester transfer protein (CETP) inhibitors are a class of drugs in the development pipeline which increase HDL-C with the goal of reducing residual risk of cardiovascular events in high-risk patients on statins. CETP inhibitors mediate the transfer of esterified cholesterol from HDL-C to atherogenic lipoprotein particles, such as LDL-C, thereby raising HDL-C and lowering LDL-C. [3] [4] [5] Four CETP inhibitors have been studied in large phase III prospective randomized control trials: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib. Trials selected adult patients with elevated cardiovascular risk, particularly those with a history of atherosclerotic vascular disease. The treatment arm (CETP inhibitor + statin) was compared with a control arm (placebo + statin). The primary outcomes were a composite of major vascular events. [4] [5] [6] Three of the 4 pivotal trials have finished. All of these trials found that CETP inhibitors displayed significant capacity to raise HDL-C levels, ranging from an increase of 30% with dalcetrapib to over 130% with evacetrapib. In spite of these findings, the CETP inhibitors did not demonstrate a reduction in cardiovascular events compared with placebo. [4] [5] [6] Due to the failure to demonstrate efficacy in cardiovascular risk reduction, development of torcetrapib, dalcetrapib, and evacetrapib has ceased. In the REVEAL trial, anacetrapib reduced cardiovascular events, but not mortality compared to placebo. 7 A separate study of how the variants in genes associated with CETP inhibitors and statins affect lipoproteins levels and cardiovascular risk suggested that a decrease in apolipoprotein B may be more predictive of cardiovascular risk than LDL levels. 8 Additional studies are needed to determine if CETP inhibitors have a place as add-on therapy or an alternative in statin-intolerant patients.
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